Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Diwakar Davar"'
Autor:
Jennifer Bordeaux, Dustin McCurry, Arivarasan Karunamurthy, Lisa H. Butterfield, Rogerio I. Neves, Anil Pahuja, Matthew P. Holtzman, Beiru Chen, Jehovana Orozco Bender, Ahmad A. Tarhini, Yan Zang, Ju Young Kim, John M. Kirkwood, Yan Lin, Cindy Sander, Joseph J. Skitzki, IlaSri B. Summit, Marc S. Ernstoff, Christian Laing, Joseph J. Drabick, Yana G. Najjar, Huang Lin, Jennifer Tsau, Ghanashyam Sarikonda, Igor Puzanov, Hassane M. Zarour, Zeni Alfonso, Amy Rose, James F. Pingpank, Diwakar Davar
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 27, iss 15
Purpose:Neoadjuvant immunotherapy may improve the clinical outcome of regionally advanced operable melanoma and allows for rapid clinical and pathologic assessment of response. We examined neoadjuvant pembrolizumab and high-dose IFNα-2b (HDI) therap
Autor:
Hassane M. Zarour, Richelle DeBlasio, Marc Schwartz, Stephanie Prescott, Ivan Vujkovic-Cvijin, Amy Rose, Marie Vétizou, Scarlett J. Ernst, Jonathan H. Badger, Howard M. Dubner, Hong Wang, Yasmine Belkaid, John M. Kirkwood, Ascharya K. Balaji, Amiran Dzutsev, Diwakar Davar, Yana G. Najjar, Quanquan Ding, Raquel Galvão Figueredo Costa, Joe-Marc Chauvin, Shuowen Zhang, Carmine Menna, Amir A. Borhani, Giorgio Trinchieri, John A. McCulloch, Bochra Zidi, Richard R. Rodrigues, Ornella Pagliano, Miriam R. Fernandes, Andrey Morgun, Robert M. Morrison, Alicia M. Cole
Publikováno v:
Cancer Research. 81:LB062-LB062
Background: Monoclonal antibodies (mAb) targeting the programmed cell death protein 1 (PD-1) receptor provide durable long-term benefit in a subset of patients (pts) with advanced melanoma with response rates of 35-42% and 4-year progression-free sur
Autor:
Carmine Menna, Amirin Dzutsev, Marie Vétizou, Jonathan H. Badger, John M. Kirkwood, John McCullogh, Hassane M. Zarour, Giorgio Trinchieri, Diwakar Davar, Ornella Pagliano
Publikováno v:
Cancer Immunology Research. 7:IA38-IA38
Immunotherapy with blocking anti-PD1 monoclonal antibodies (a PD1 mAbs) has become one of the most potent therapies of melanoma, providing extended clinical benefits to 30-40% advanced melanoma patients. There is substantial evidence that pre-existin